Danuglipron

Danuglipron
Clinical data
Other names	PF-06882961
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid;
CAS Number	2230198-02-2;
PubChem CID	134611040;
ChemSpider	81367976;
UNII	DN9IUI24GP;
KEGG	D11910;
ChEBI	CHEBI:231951;
ChEMBL	ChEMBL4518483;
CompTox Dashboard (EPA)	DTXSID601101457 ;
Chemical and physical data
Formula	C31H30FN5O4
Molar mass	555.610 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1;
	InChI InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1; Key:HYBAKUMPISVZQP-DEOSSOPVSA-N;

Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer^[1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.^[2]^[3] However, in April 2025, Pfizer announced it would abandon further development of danuglipron due to unpredictable liver toxicity.^[4]